Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-09-06
2011-10-25
Peng, Bo (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024320, C435S320100, C435S006120, C424S184100, C424S186100, C424S187100, C424S188100
Reexamination Certificate
active
08044185
ABSTRACT:
Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
REFERENCES:
patent: 5869624 (1999-02-01), Hasel et al.
patent: 5922325 (1999-07-01), Tilley et al.
patent: 6432675 (2002-08-01), Crea
patent: 6710173 (2004-03-01), Binley et al.
patent: 6716429 (2004-04-01), Sodroski et al.
patent: 6908617 (2005-06-01), Wyatt et al.
patent: 7022324 (2006-04-01), Binley et al.
patent: 7048929 (2006-05-01), Sodroski et al.
patent: 2005/0025779 (2005-02-01), Berman et al.
patent: WO 99/24465 (1999-05-01), None
patent: WO 99/24553 (1999-05-01), None
patent: WO 00/58438 (2000-10-01), None
patent: WO 01/72123 (2001-10-01), None
patent: WO 2007/030637 (2007-03-01), None
Bette Korber et al., “Numbering Positions in HIV Relative to HXB2CG” Human Retroviruses and AIDS, 1998, pp. III-102 to III-111.
Desrosiers RC. “Prospects for an ADIS vaccine” Nature Medicine vol. 10 (2004), pp. 221-223.
Burton et al. “HIV vaccine design and the neutralizing antibody problem” Nature Immunology; 5(3):233-236, 2004.
Ashish et al., “Binding of Full-length HIV-1 gp120 to CD4 Induces Structural Reorientation Around the gp120 Core,”Biophysical Journal-Biophysical Letters, pp. L01-L03 (2006).
Burton, Dennis R., “Antibodies, viruses and vaccines,”Nature Review, 2:706-713 (2002).
Chen et al., “Determining the Structure of an Unliganded and Fully Glycosylated SIV gp120 Envelope Glycoprotein,”Structure, Current Biology Ltd., 13(2):197-211 (2005).
Dey et al., “Neutralizing of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor,”Journal of Virology, 77(5):2859-2865 (2003).
Huang et al., “Scorpion-Toxin Mimics of CD4 in Complex with Human Immunodeficiency Virus gp120: Crystal Structures, Molecular Mimicry, and Neutralization Breadth,”Structure, 13:755-768 (2005).
Huang et al., “Structure of a V3-Containing HIV-1 gp120 Core,”Science, 310:1025-1028 (2005).
Kwong et al., “HIV-1 GP120 Core Complexed with CD4 and a Neutralizing Human Antibody,”Nature, 393(648):1-105 (1998).
Kwong et al., “Structure of an HIV GP 120 Envelope Glycoprotein in Complex with the CD4 Receptor and a Neutralizing Human Antibody,”Nature, 393:648-659 (1998).
Kwong et al., “Structures of HIV-1 gp120 envelope glycoprotein from laboratory-adapted and primary isolates,”Structures, Current Biology Ltd., 8(12):1329-1339 (2000).
Moulard et al., “Broadly cross-reactive HIV-1-neutralizing human monocolonal Fab selected for binding to gp120-CD4-CCR5 complexes,”PNAS, 99(10):6913-6918 (2002).
Myszka et al., “Energetics of the HIV gp120-CD4 binding reaction,”PNAS, 97(16):9026-9031 (2000).
Pan et al., “CD4 Binding Partially Locks the Bridging Sheet in gp120 but Leaves the beta2/3 Strands Flexible,”Journal of Molecular Biology, 350(3):514-527 (2005).
Reynard et al., “HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity,”Virology, 324(1):90-102 (2004).
Satoh et al., “Bioactive Peptide Design Based on Protein Surface Epitopes,”The Journal of Biological Chemistry, 272(18): 12175-12180 (1997).
Schülke et al., “Oligomeric and Conformational Properties of a Proteolytically Mature Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein,”Journal of Virology, 76(15):7760-7776 (2002).
Stanfield et al., “Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop,”Virology, 315(1):159-173 (2003). Abstract only.
Wang et al., “Uncommon gp120 Cysteine Residues Found in Primary HIV-1 Isolates,”Aids Research and Human Retroviruses, 11(1):185-188 (1995).
Wyatt et al., “Structure of the Core of the HIV-1 gp120 Exterior Envelope Glycoprotein,”Analysis, pp. III-3-III-9 (1998).
Wyatt et al., “The Antigenic Structure of the HIV gp120 Envelope Glycoprotein,”Nature, 393:705-711 (1998).
Xiang et al., “CD4-Bound Conformation of HIV-1 gp120 Improved by Introduced Disulfide Bonds,” 9thConference on Retroviruses and Opportunistic Infections, 2002 <http.retroconference.org/2002/Abstract/12607.htm>.
Xiang et al., “Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein,”Journal of Virology, 76(19):9888-9899 (2002).
Yang et al., “Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1,”Journal of Virology, 78(23):12975-12986 (2004).
Dey Barna
Huang Chih-Chin
Kwong Peter
Mascola John
Nabel Gary
Dana Farber Cancer Institute, Inc.
Klarquist & Sparkman, LLP
Peng Bo
The United States of America as represented by the Secretary of
LandOfFree
Conformationally stabilized HIV envelope immunogens and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conformationally stabilized HIV envelope immunogens and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally stabilized HIV envelope immunogens and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4281132